139 related articles for article (PubMed ID: 19116621)
1. Trial watch: Protease inhibitors show promise against HCV.
Nat Rev Drug Discov; 2009 Jan; 8(1):11. PubMed ID: 19116621
[No Abstract] [Full Text] [Related]
2. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
White PW; Llinas-Brunet M; Bös M
Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
[No Abstract] [Full Text] [Related]
3. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
4. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
[TBL] [Abstract][Full Text] [Related]
6. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
7. Virology: fresh assault on hepatitis C.
Rice CM
Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
[No Abstract] [Full Text] [Related]
8. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
[No Abstract] [Full Text] [Related]
9. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
[TBL] [Abstract][Full Text] [Related]
10. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
Lemon SM; Yi M; Li K
Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
[No Abstract] [Full Text] [Related]
11. Serine protease inhibitors as anti-hepatitis C virus agents.
Reiser M; Timm J
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
[TBL] [Abstract][Full Text] [Related]
12. Molecule of the month. Telaprevir.
Drug News Perspect; 2010 Jun; 23(5):329. PubMed ID: 20603656
[No Abstract] [Full Text] [Related]
13. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V
J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623
[TBL] [Abstract][Full Text] [Related]
14. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
Thomson JA; Perni RB
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic strategies in HCV: second-generation protease inhibitors.
Clark VC; Peter JA; Nelson DR
Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850
[TBL] [Abstract][Full Text] [Related]
17. Infectious diseases. First specific drugs raise hopes for hepatitis C.
Enserink M
Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
[No Abstract] [Full Text] [Related]
18. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
[TBL] [Abstract][Full Text] [Related]
19. Recent development of therapeutics for chronic HCV infection.
Huang Z; Murray MG; Secrist JA
Antiviral Res; 2006 Sep; 71(2-3):351-62. PubMed ID: 16828888
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
Slater MJ; Andrews DM; Baker G; Bethell SS; Carey S; Chaignot H; Clarke B; Coomber B; Ellis M; Good A; Gray N; Hardy G; Jones P; Mills G; Robinson E
Bioorg Med Chem Lett; 2002 Dec; 12(23):3359-62. PubMed ID: 12419361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
